<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402986</url>
  </required_header>
  <id_info>
    <org_study_id>CD-RI-CAT-354-1049</org_study_id>
    <secondary_id>2011-001360-21</secondary_id>
    <nct_id>NCT01402986</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Tralokinumab in Adults With Asthma</brief_title>
  <official_title>A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of tralokinumab to standard
      asthma medication is effective in the treatment of adults with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interleukin-13 (IL-13) is a key mediator in the pathogenesis of established asthmatic
      disease. Tralokinumab is a human monoclonal antibody that blocks IL-13, which may result in
      improved control of asthma. This study will determine whether the addition of tralokinumab to
      standard asthma medications results in a reduced rate of asthma exacerbations in subjects
      with severe asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER)</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids (OCS) is administered (10 days after administration of an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FEV1 and FVC at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Ratio of FEV1/FVC was analysed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home</measure>
    <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home</measure>
    <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53</measure>
    <time_frame>Week 53</time_frame>
    <description>The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems) that reflects increasing levels of difficulty. The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53</measure>
    <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>There were 3 symptom questions in the ASMA diary: daytime frequency (question 1), daytime severity (question 2) and nighttime severity (question 6). All symptom questions were scored from 0 to 4 averaged, where a higher score indicated greater frequency or severity. Daily Asthma symptom scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rescue Medication Use at Week 53</measure>
    <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>Rescue medication use was collected from 3 questions: daytime use in response to symptoms (question 3), daytime prophylactic use (question 4) and nighttime use (question 7). Rescue medication use questions were first assessed using a dichotomous response option (YES/NO). If the participants reported YES, there was a subsequent question about the number of times rescue medication was used (questions 3a, 4a, and 7a). Daily average scores were summarized each week for all participants with at least 4 non-missing records each week. Days with no reported rescue medication use were represented as 0 and included in the calculation with participants who reported yes and completed questions 3a, 4a and 7a. The baseline scores were calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)</measure>
    <time_frame>Baseline and Week 75</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Week 75 that were absent before treatment or that worsened relative to pre-treatment state. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Serum Tralokinumab Concentration at Week 53</measure>
    <time_frame>Week 53</time_frame>
    <description>Tralokinumab concentrations that were below limit of quantification (LOQ) of the pharmacokinetic (PK) assay (LOQ = 0.500 microgram per milliliter [mcg/mL]) were replaced by LOQ/2 = 0.250 mcg/mL; results were reported to 3 significant figures level of precision. Observed serum tralokinumab concentration at Week 53 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADA) to Tralokinumab</measure>
    <time_frame>Baseline and Week 75</time_frame>
    <description>Immunogenicity assessment included determination of anti-drug (tralokinumab) antibodies in serum samples. ADA positive was defined as a titer greater than or equal to (&gt;=13) at any point in the study. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Annual Asthma Exacerbation Rate (AER)</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Severe annualized AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids is administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Exacerbation Through Week 53</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe Exacerbation Through Week 53</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline serum periostin greater than or equal to (&gt;=) or less than (&lt;) median, &gt;= or &lt; 25th percentile and &gt;= or &lt; 75th percentile. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Th2 status. Th2-high included those participants who had immunoglobulin E (IgE) &gt;100 international unit per milliliter (IU/mL) and blood eosinophils &gt;= 0.14 * 10 power 9 per Liter. Th2 low would include those participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroups baseline peripheral blood eosinophil counts. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup baseline FEV1 reversibility &gt;=12% and &lt;12%. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline FEV1% predicaed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup as asthma exacerbations in the past year. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER evaluated by subgroup baseline serum periostin. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup FEV1 reversibility. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Severe AER was assessed based on AER data up to Week 53. An asthma exacerbation is a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. It was considered resolved 7 days after last dose of OCS administered (10 days after injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup Th2 status. Th2-high include participants who had IgE &gt;100 IU/mL and blood eosinophils &gt;=0.14*10^9/Liter. Th2 low would include participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup baseline peripheral blood eosinophil count. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Prebronchodilator FEV1 was evaluated by subgroups. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Atopic and Non-atopic asthma status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate (AER) by Chronic OCS Use</measure>
    <time_frame>Week 1 up to Week 53</time_frame>
    <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup chronic OCS use. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Nighttime Awakening at Week 53</measure>
    <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>Scores for nighttime awakenings were generated based on the single item (question 5) that had a dichotomous response option (YES/NO). Nighttime awakenings were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated with data from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Activity Limitations at Week 53</measure>
    <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>There were 3 activity limitation questions in the ASMA diary. All activity questions were scored from 0 to 4 and averaged, where the higher score indicated greater limitation. Activity limitation scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FEV1 was measured in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FEV6 was measured in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FVC was measured in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
    <description>Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for IC was measured in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home</measure>
    <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home</measure>
    <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
    <description>The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">689</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo, Q2W - Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tralokinumab 300 mg, Q2W - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Q2/4W - Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tralokinumab 300 mg, Q2/4W - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Q2W</intervention_name>
    <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
    <arm_group_label>Placebo, Q2W - Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tralokinumab 300 mg, Q2W</intervention_name>
    <description>Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.</description>
    <arm_group_label>Tralokinumab 300 mg, Q2W - Cohort 1</arm_group_label>
    <other_name>CAT-354</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Q2/4W</intervention_name>
    <description>Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.</description>
    <arm_group_label>Placebo, Q2/4W - Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tralokinumab 300 mg, Q2/4W</intervention_name>
    <description>Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.</description>
    <arm_group_label>Tralokinumab 300 mg, Q2/4W - Cohort 2</arm_group_label>
    <other_name>CAT-354</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Body mass index (BMI) between 16-40 kilogram per square meter (kg/m^2) at Visit 1

          -  Uncontrolled severe asthma

          -  A chest x-ray with no abnormality

          -  Females of childbearing potential who are sexually active with a non-sterilized male
             partner must use highly effective contraception from Day 1

          -  Non-sterilized males or sterilized males who are less than or equal to (=&lt;) 1 year
             post-vasectomy who are sexually active with a female partner of childbearing potential
             must use a highly effective method of contraception

        Exclusion Criteria:

          -  Employee of the clinical study site or any other individuals directly involved with
             the conduct of the study, or immediate family members of such individuals

          -  Pregnant or breastfeeding women

          -  Any other respiratory disease

          -  Previously taken tralokinumab (the study drug)

          -  Current smoker or a history of smoking which would be more than 1 pack per day for 10
             years

          -  Known immune deficiency

          -  History of cancer

          -  Hepatitis B, C or Human Immuno-deficiency Virus (HIV)

          -  Any disease which may cause complications whilst taking the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Piper, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Brightling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Lung Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cocoa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monte Grande</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ranelagh</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quillota</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille Cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 18</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujisawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Habikino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kahoku-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sumida-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomakomai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wakayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Culiacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Querétaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villahermosa</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagunto(Valencia)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=51&amp;filename=CAT-354_CP1049_Protocol_Legal%20IP_Redacted_02Sep14.pdf</url>
    <description>CD-RI-CAT-354-1049 Redacted Protocol</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=51&amp;filename=CAT-354_CP1049_SAP_08Aug14.pdf</url>
    <description>CD-RI-CAT-354-1049 SAP</description>
  </link>
  <reference>
    <citation>Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Sep;3(9):692-701. doi: 10.1016/S2213-2600(15)00197-6. Epub 2015 Jul 28.</citation>
    <PMID>26231288</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <results_first_submitted>May 31, 2016</results_first_submitted>
  <results_first_submitted_qc>January 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Tralokinumab</keyword>
  <keyword>CAT-354</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 689 participants were screened, out of which 452 participants were randomized into this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Q2W - Cohort 1</title>
          <description>Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
          <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Q2/4W - Cohort 2</title>
          <description>Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
        </group>
        <group group_id="P4">
          <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
          <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intention-to-treat (ITT) population included all participants who were randomized into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo, Q2W - Cohort 1</title>
          <description>Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
          <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo, Q2/4W - Cohort 2</title>
          <description>Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
        </group>
        <group group_id="B4">
          <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
          <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="151"/>
            <count group_id="B5" value="452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="12.1"/>
                    <measurement group_id="B2" value="49.7" spread="12.2"/>
                    <measurement group_id="B3" value="51.7" spread="13.6"/>
                    <measurement group_id="B4" value="50.5" spread="11.8"/>
                    <measurement group_id="B5" value="50.1" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Asthma Exacerbation Rate (AER)</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids (OCS) is administered (10 days after administration of an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The intent-to-treat (ITT) population included all participants who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER)</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids (OCS) is administered (10 days after administration of an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The intent-to-treat (ITT) population included all participants who were randomized into the study.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.75" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.76" upper_limit="1.08"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.81" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 95 percent (%) confidence interval (CI) for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 versus [vs] more than [&gt;] 2 but less than or equal to [=&lt;] 6), atopic asthma status (atopic/non-atopic), chronic oral corticosteroid (OCS) use (presence vs absence) and geographical region as the covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.709</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt; 2 but =&lt; 6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53</title>
        <description>Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53</title>
          <description>Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator: Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.926" spread="0.050"/>
                    <measurement group_id="O2" value="1.922" spread="0.056"/>
                    <measurement group_id="O3" value="1.934" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.153" spread="0.053"/>
                    <measurement group_id="O2" value="2.094" spread="0.061"/>
                    <measurement group_id="O3" value="2.110" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator: Week 53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.035"/>
                    <measurement group_id="O2" value="0.128" spread="0.032"/>
                    <measurement group_id="O3" value="0.032" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Week 53 (n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.058" spread="0.027"/>
                    <measurement group_id="O2" value="0.085" spread="0.029"/>
                    <measurement group_id="O3" value="-0.009" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53</title>
        <description>Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53</title>
          <description>Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator: Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.830" spread="0.064"/>
                    <measurement group_id="O2" value="2.809" spread="0.072"/>
                    <measurement group_id="O3" value="2.827" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.055" spread="0.067"/>
                    <measurement group_id="O2" value="2.981" spread="0.075"/>
                    <measurement group_id="O3" value="2.980" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator: Week 53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.036"/>
                    <measurement group_id="O2" value="0.117" spread="0.037"/>
                    <measurement group_id="O3" value="0.003" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Week 53 (n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.057" spread="0.030"/>
                    <measurement group_id="O2" value="0.060" spread="0.033"/>
                    <measurement group_id="O3" value="-0.024" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53</title>
        <description>Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53</title>
          <description>Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator: Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.003" spread="0.069"/>
                    <measurement group_id="O2" value="2.955" spread="0.075"/>
                    <measurement group_id="O3" value="2.993" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.225" spread="0.072"/>
                    <measurement group_id="O2" value="3.133" spread="0.078"/>
                    <measurement group_id="O3" value="3.125" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator: Week 53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.039"/>
                    <measurement group_id="O2" value="0.110" spread="0.042"/>
                    <measurement group_id="O3" value="-0.018" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Week 53 (n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.071" spread="0.032"/>
                    <measurement group_id="O2" value="0.045" spread="0.034"/>
                    <measurement group_id="O3" value="-0.030" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53</title>
        <description>Pre- and post-bronchodilator FEV1 and FVC at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Ratio of FEV1/FVC was analysed. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53</title>
          <description>Pre- and post-bronchodilator FEV1 and FVC at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Ratio of FEV1/FVC was analysed. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage of ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator: Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.508" spread="0.986"/>
                    <measurement group_id="O2" value="65.071" spread="1.013"/>
                    <measurement group_id="O3" value="65.008" spread="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.152" spread="0.997"/>
                    <measurement group_id="O2" value="66.831" spread="1.056"/>
                    <measurement group_id="O3" value="67.883" spread="1.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator: Week 53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.320" spread="0.685"/>
                    <measurement group_id="O2" value="1.695" spread="0.517"/>
                    <measurement group_id="O3" value="1.155" spread="0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Week 53 (n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.512" spread="0.513"/>
                    <measurement group_id="O2" value="1.593" spread="0.563"/>
                    <measurement group_id="O3" value="0.032" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53</title>
        <description>Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53</title>
          <description>Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator: Baseline (n=140,138,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.001"/>
                    <measurement group_id="O2" value="0.023" spread="0.001"/>
                    <measurement group_id="O3" value="0.023" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Baseline (n=140,133,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.001"/>
                    <measurement group_id="O2" value="0.024" spread="0.001"/>
                    <measurement group_id="O3" value="0.024" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-bronchodilator: Week 53 (n=108,109,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.001"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                    <measurement group_id="O3" value="0.001" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator: Week 53 (n=108,109,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.001"/>
                    <measurement group_id="O2" value="0.001" spread="0.001"/>
                    <measurement group_id="O3" value="0.000" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home</title>
        <description>Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home</title>
          <description>Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1-7: Morning (n=151,149,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.05"/>
                    <measurement group_id="O2" value="1.61" spread="0.05"/>
                    <measurement group_id="O3" value="1.66" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365-371: Morning (n=124,119,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.06"/>
                    <measurement group_id="O2" value="0.01" spread="0.04"/>
                    <measurement group_id="O3" value="-0.07" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1-7: Evening (n=149,147,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.05"/>
                    <measurement group_id="O2" value="1.68" spread="0.05"/>
                    <measurement group_id="O3" value="1.65" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365-371: Evening (n=120,116,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.05"/>
                    <measurement group_id="O2" value="-0.08" spread="0.05"/>
                    <measurement group_id="O3" value="-0.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home</title>
        <description>The PEF is a participant’s maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home</title>
          <description>The PEF is a participant’s maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>liters per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1-7: Morning (n=151,149,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.7" spread="8.7"/>
                    <measurement group_id="O2" value="271.0" spread="9.7"/>
                    <measurement group_id="O3" value="281.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365-371: Morning (n=124,119,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="8.8"/>
                    <measurement group_id="O2" value="-8.0" spread="7.9"/>
                    <measurement group_id="O3" value="-24.0" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1-7: Evening (n=149,147,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.0" spread="8.9"/>
                    <measurement group_id="O2" value="287.6" spread="9.9"/>
                    <measurement group_id="O3" value="283.8" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365-371: Evening (n=120,116,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="8.7"/>
                    <measurement group_id="O2" value="-27.0" spread="8.2"/>
                    <measurement group_id="O3" value="-36.5" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53</title>
        <description>Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53</title>
          <description>Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=149,147,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.07"/>
                    <measurement group_id="O2" value="2.59" spread="0.09"/>
                    <measurement group_id="O3" value="2.54" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 53 (n=118,115,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.10"/>
                    <measurement group_id="O2" value="-1.02" spread="0.10"/>
                    <measurement group_id="O3" value="-0.93" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53</title>
        <description>AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53</title>
          <description>AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Overall (n=147,142,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="0.09"/>
                    <measurement group_id="O2" value="3.98" spread="0.09"/>
                    <measurement group_id="O3" value="4.08" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53: Overall (n=107,109,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.10"/>
                    <measurement group_id="O2" value="1.04" spread="0.10"/>
                    <measurement group_id="O3" value="1.00" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Symptoms (n=147,142,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="0.09"/>
                    <measurement group_id="O2" value="4.03" spread="0.09"/>
                    <measurement group_id="O3" value="4.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53: Symptoms (n=107,109,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.11"/>
                    <measurement group_id="O2" value="1.14" spread="0.12"/>
                    <measurement group_id="O3" value="1.05" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Activity limitation (n=147,142,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="0.08"/>
                    <measurement group_id="O2" value="4.04" spread="0.09"/>
                    <measurement group_id="O3" value="4.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53: Activity limitation (n=107,109,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.10"/>
                    <measurement group_id="O2" value="0.96" spread="0.10"/>
                    <measurement group_id="O3" value="0.93" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Emotional Function (n=147,142,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="0.12"/>
                    <measurement group_id="O2" value="3.91" spread="0.12"/>
                    <measurement group_id="O3" value="4.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53: Emotional Function (n=107,109,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.12"/>
                    <measurement group_id="O2" value="1.10" spread="0.12"/>
                    <measurement group_id="O3" value="1.09" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Environmental stimuli (n=147,142,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="0.11"/>
                    <measurement group_id="O2" value="3.76" spread="0.12"/>
                    <measurement group_id="O3" value="3.89" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53: Environmental stimuli (n=107,109,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.13"/>
                    <measurement group_id="O2" value="0.86" spread="0.14"/>
                    <measurement group_id="O3" value="0.97" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53</title>
        <description>The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems) that reflects increasing levels of difficulty. The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53</title>
          <description>The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems) that reflects increasing levels of difficulty. The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility - No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="0.10"/>
                    <measurement group_id="O2" value="118" spread="0.10"/>
                    <measurement group_id="O3" value="106" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility - Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="0.12"/>
                    <measurement group_id="O2" value="18" spread="0.12"/>
                    <measurement group_id="O3" value="23" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility - Severe Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.12"/>
                    <measurement group_id="O2" value="0" spread="0.12"/>
                    <measurement group_id="O3" value="1" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="0.13"/>
                    <measurement group_id="O2" value="14" spread="0.14"/>
                    <measurement group_id="O3" value="21" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care - No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care - Moderate Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care - Severe Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities - No Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities - Moderate Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities - Severe Problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort - No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort - Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort - Severe problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression - No problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression - Moderate problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression - Severe problem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53</title>
        <description>The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53</title>
          <description>The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.6"/>
                    <measurement group_id="O2" value="9.3" spread="1.9"/>
                    <measurement group_id="O3" value="7.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53</title>
        <description>There were 3 symptom questions in the ASMA diary: daytime frequency (question 1), daytime severity (question 2) and nighttime severity (question 6). All symptom questions were scored from 0 to 4 averaged, where a higher score indicated greater frequency or severity. Daily Asthma symptom scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
        <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53</title>
          <description>There were 3 symptom questions in the ASMA diary: daytime frequency (question 1), daytime severity (question 2) and nighttime severity (question 6). All symptom questions were scored from 0 to 4 averaged, where a higher score indicated greater frequency or severity. Daily Asthma symptom scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 - Day -1 (Baseline) (n=151,147,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.71"/>
                    <measurement group_id="O2" value="1.49" spread="0.77"/>
                    <measurement group_id="O3" value="1.56" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365 - Day 371 (n=113,108,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.75"/>
                    <measurement group_id="O2" value="-0.42" spread="0.73"/>
                    <measurement group_id="O3" value="-0.49" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rescue Medication Use at Week 53</title>
        <description>Rescue medication use was collected from 3 questions: daytime use in response to symptoms (question 3), daytime prophylactic use (question 4) and nighttime use (question 7). Rescue medication use questions were first assessed using a dichotomous response option (YES/NO). If the participants reported YES, there was a subsequent question about the number of times rescue medication was used (questions 3a, 4a, and 7a). Daily average scores were summarized each week for all participants with at least 4 non-missing records each week. Days with no reported rescue medication use were represented as 0 and included in the calculation with participants who reported yes and completed questions 3a, 4a and 7a. The baseline scores were calculated from Day -7 to Day -1. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rescue Medication Use at Week 53</title>
          <description>Rescue medication use was collected from 3 questions: daytime use in response to symptoms (question 3), daytime prophylactic use (question 4) and nighttime use (question 7). Rescue medication use questions were first assessed using a dichotomous response option (YES/NO). If the participants reported YES, there was a subsequent question about the number of times rescue medication was used (questions 3a, 4a, and 7a). Daily average scores were summarized each week for all participants with at least 4 non-missing records each week. Days with no reported rescue medication use were represented as 0 and included in the calculation with participants who reported yes and completed questions 3a, 4a and 7a. The baseline scores were calculated from Day -7 to Day -1. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>use per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 - Day -1 (Baseline) (n=151,147,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="2.73"/>
                    <measurement group_id="O2" value="2.77" spread="3.78"/>
                    <measurement group_id="O3" value="2.38" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365 - Day 371 (n=113,108,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="2.20"/>
                    <measurement group_id="O2" value="-0.77" spread="2.59"/>
                    <measurement group_id="O3" value="-1.02" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Week 75 that were absent before treatment or that worsened relative to pre-treatment state. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 75</time_frame>
        <population>The safety population included all participants who received any investigational product and had safety data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Week 75 that were absent before treatment or that worsened relative to pre-treatment state. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The safety population included all participants who received any investigational product and had safety data available for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" spread="17.12"/>
                    <measurement group_id="O2" value="134" spread="19.83"/>
                    <measurement group_id="O3" value="128" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="1.6"/>
                    <measurement group_id="O2" value="18" spread="1.9"/>
                    <measurement group_id="O3" value="25" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Serum Tralokinumab Concentration at Week 53</title>
        <description>Tralokinumab concentrations that were below limit of quantification (LOQ) of the pharmacokinetic (PK) assay (LOQ = 0.500 microgram per milliliter [mcg/mL]) were replaced by LOQ/2 = 0.250 mcg/mL; results were reported to 3 significant figures level of precision. Observed serum tralokinumab concentration at Week 53 was reported.</description>
        <time_frame>Week 53</time_frame>
        <population>The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here &quot;N&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serum Tralokinumab Concentration at Week 53</title>
          <description>Tralokinumab concentrations that were below limit of quantification (LOQ) of the pharmacokinetic (PK) assay (LOQ = 0.500 microgram per milliliter [mcg/mL]) were replaced by LOQ/2 = 0.250 mcg/mL; results were reported to 3 significant figures level of precision. Observed serum tralokinumab concentration at Week 53 was reported.</description>
          <population>The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here &quot;N&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="34.2"/>
                    <measurement group_id="O2" value="25.8" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Drug Antibodies (ADA) to Tralokinumab</title>
        <description>Immunogenicity assessment included determination of anti-drug (tralokinumab) antibodies in serum samples. ADA positive was defined as a titer greater than or equal to (&gt;=13) at any point in the study. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Baseline and Week 75</time_frame>
        <population>The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Drug Antibodies (ADA) to Tralokinumab</title>
          <description>Immunogenicity assessment included determination of anti-drug (tralokinumab) antibodies in serum samples. ADA positive was defined as a titer greater than or equal to (&gt;=13) at any point in the study. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 1) (n=151,150,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="17.12"/>
                    <measurement group_id="O2" value="0.67" spread="19.83"/>
                    <measurement group_id="O3" value="1.3" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 75 (n=151,150,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Annual Asthma Exacerbation Rate (AER)</title>
        <description>Severe annualized AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids is administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Annual Asthma Exacerbation Rate (AER)</title>
          <description>Severe annualized AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids is administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.10" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.06" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.10" lower_limit="0.05" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.293</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.270</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Exacerbation Through Week 53</title>
        <description>Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Exacerbation Through Week 53</title>
          <description>Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events.</measurement>
                    <measurement group_id="O2" value="NA">The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events.</measurement>
                    <measurement group_id="O3" value="NA">The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.257</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.225</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe Exacerbation Through Week 53</title>
        <description>Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe Exacerbation Through Week 53</title>
          <description>Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events.</measurement>
                    <measurement group_id="O2" value="NA">The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events.</measurement>
                    <measurement group_id="O3" value="NA">The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.538</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.561</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline serum periostin greater than or equal to (&gt;=) or less than (&lt;) median, &gt;= or &lt; 25th percentile and &gt;= or &lt; 75th percentile. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline serum periostin greater than or equal to (&gt;=) or less than (&lt;) median, &gt;= or &lt; 25th percentile and &gt;= or &lt; 75th percentile. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= median (n=67,81,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.88" upper_limit="1.43"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.65" upper_limit="1.08"/>
                    <measurement group_id="O3" value="1.27" lower_limit="1.03" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; median (n=84,69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.55" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.76" upper_limit="1.25"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.45" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 25th Percentile (n=105,115,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.75" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.67" upper_limit="1.03"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.87" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 25th Percentile (n=46,35,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.58" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.81" upper_limit="1.56"/>
                    <measurement group_id="O3" value="0.65" lower_limit="0.38" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75th Percentile (n=32,43,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.76" upper_limit="1.60"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.65" upper_limit="1.25"/>
                    <measurement group_id="O3" value="2.03" lower_limit="1.60" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 75th Percentile (n=119,107,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.69" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.73" upper_limit="1.11"/>
                    <measurement group_id="O3" value="0.60" lower_limit="0.46" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.856</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.703</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 25th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.455</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 25th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.929</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.507</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 75th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.716</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 75th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.328</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.804</p_value>
            <method>Poission regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th Percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Th2 status. Th2-high included those participants who had immunoglobulin E (IgE) &gt;100 international unit per milliliter (IU/mL) and blood eosinophils &gt;= 0.14 * 10 power 9 per Liter. Th2 low would include those participants who do not meet Th2 high status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Th2 status. Th2-high included those participants who had immunoglobulin E (IgE) &gt;100 international unit per milliliter (IU/mL) and blood eosinophils &gt;= 0.14 * 10 power 9 per Liter. Th2 low would include those participants who do not meet Th2 high status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Th2 high (n=70,74,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.74" upper_limit="1.23"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.73" upper_limit="1.20"/>
                    <measurement group_id="O3" value="1.09" lower_limit="0.85" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 Low (n=73,61,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.69" upper_limit="1.16"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.66" upper_limit="1.16"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.64" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.922</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 Low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 Low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.813</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroups baseline peripheral blood eosinophil counts. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroups baseline peripheral blood eosinophil counts. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 150 cells/mcgL (n=95,104,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.76" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.66" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.77" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 150 cells/mcgL (n=48,38,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.64" upper_limit="1.22"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.78" upper_limit="1.48"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.69" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 300 cells/mcgL (n=54,60,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.74" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.76" upper_limit="1.31"/>
                    <measurement group_id="O3" value="1.56" lower_limit="1.23" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 300 cells/mcgL (n=89,82,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.70" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.64" upper_limit="1.06"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.47" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &gt;=150 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.335</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &gt;=150 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.586</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &lt;150 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.331</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &lt;150 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &gt;=300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &gt;=300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.463</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &lt;300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.793</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &lt;300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup baseline FEV1 reversibility &gt;=12% and &lt;12%. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup baseline FEV1 reversibility &gt;=12% and &lt;12%. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reversibility &gt;=12% (n=57,43,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.65" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.45" upper_limit="0.99"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.80" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reversibility &lt;12% (n=91,101,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.73" upper_limit="1.16"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.80" upper_limit="1.21"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.71" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;=12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;=12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.438</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt;12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.947</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt;12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.916</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline FEV1% predicaed. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline FEV1% predicaed. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1% Predicted &lt;=60% (n=49,45,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.77" upper_limit="1.40"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.68" upper_limit="1.29"/>
                    <measurement group_id="O3" value="1.67" lower_limit="1.34" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1% Predicted &lt;=80% (n=119,109,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.76" upper_limit="1.13"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.71" upper_limit="1.08"/>
                    <measurement group_id="O3" value="1.13" lower_limit="0.93" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1% predicted &lt;=60%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.723</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1% predicted &lt;=60%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.852</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1% predicted &lt;=80%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1% predicted &lt;=80%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup as asthma exacerbations in the past year. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup as asthma exacerbations in the past year. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 asthma exacerbations (n=97,96,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.47" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.45" upper_limit="0.79"/>
                    <measurement group_id="O3" value="0.45" lower_limit="0.32" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2 but &lt; 6 asthma exacerbations (n=54,54,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" lower_limit="1.12" upper_limit="1.82"/>
                    <measurement group_id="O2" value="1.42" lower_limit="1.12" upper_limit="1.78"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.52" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.802</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.792</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.231</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin</title>
        <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER evaluated by subgroup baseline serum periostin. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin</title>
          <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER evaluated by subgroup baseline serum periostin. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= median (n=67,81,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.14" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.03" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.06" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; median (n=84,69,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.04" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.06" upper_limit="0.26"/>
                    <measurement group_id="O3" value="0.08" lower_limit="0.03" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Serum Periostin &gt;=Median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Serum Periostin &gt;=Median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.197</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline Serum Periostin &lt; Median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline Serum Periostin &lt; Median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility</title>
        <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup FEV1 reversibility. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility</title>
          <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup FEV1 reversibility. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reversibility &gt;=12% (n=57,43,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.04" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.04" upper_limit="0.29"/>
                    <measurement group_id="O3" value="0.13" lower_limit="0.05" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reversibility &lt;12% (n=91,101,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.12" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.05" upper_limit="0.19"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.04" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;=12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.975</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>7.67</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;=12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.473</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>6.67</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt;12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt;12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status</title>
        <description>Severe AER was assessed based on AER data up to Week 53. An asthma exacerbation is a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. It was considered resolved 7 days after last dose of OCS administered (10 days after injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup Th2 status. Th2-high include participants who had IgE &gt;100 IU/mL and blood eosinophils &gt;=0.14*10^9/Liter. Th2 low would include participants who do not meet Th2 high status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status</title>
          <description>Severe AER was assessed based on AER data up to Week 53. An asthma exacerbation is a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. It was considered resolved 7 days after last dose of OCS administered (10 days after injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup Th2 status. Th2-high include participants who had IgE &gt;100 IU/mL and blood eosinophils &gt;=0.14*10^9/Liter. Th2 low would include participants who do not meet Th2 high status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Th2 high (n=70,74,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.05" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.05" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.02" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 Low (n=73,61,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.11" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.01" upper_limit="0.15"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.05" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.698</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 Low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 Low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.576</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count</title>
        <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup baseline peripheral blood eosinophil count. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count</title>
          <description>Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup baseline peripheral blood eosinophil count. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 300 cells/mcgL (n=54,60,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.11" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.07" upper_limit="0.31"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.06" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 300 cells/mcgL (n=89,82,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.07" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.03" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.08" lower_limit="0.03" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &gt;=300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &gt;=300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &lt;300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline eosinophil count &lt;300 cells/mcgL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.661</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups</title>
        <description>Prebronchodilator FEV1 was evaluated by subgroups. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups</title>
          <description>Prebronchodilator FEV1 was evaluated by subgroups. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline SP &gt;=median (n=54,71,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="2.75" lower_limit="0.88" upper_limit="1.43"/>
                    <measurement group_id="O2" value="10.48" spread="3.01" lower_limit="0.65" upper_limit="1.08"/>
                    <measurement group_id="O3" value="4.36" spread="2.25" lower_limit="1.03" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt;median (n=71,59,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="2.82" lower_limit="0.55" upper_limit="0.95"/>
                    <measurement group_id="O2" value="7.46" spread="3.00" lower_limit="0.76" upper_limit="1.25"/>
                    <measurement group_id="O3" value="1.30" spread="2.12" lower_limit="0.45" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &gt;=25th Percentile (n=88,102,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="2.29" lower_limit="0.75" upper_limit="1.15"/>
                    <measurement group_id="O2" value="10.40" spread="2.43" lower_limit="0.67" upper_limit="1.03"/>
                    <measurement group_id="O3" value="2.31" spread="1.66" lower_limit="0.87" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt;25th Percentile (n=37,28,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="3.92" lower_limit="0.58" upper_limit="1.16"/>
                    <measurement group_id="O2" value="4.40" spread="4.39" lower_limit="0.81" upper_limit="1.56"/>
                    <measurement group_id="O3" value="5.99" spread="4.22" lower_limit="0.38" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &gt;=75th Percentile (n=25,40,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="4.07" lower_limit="0.76" upper_limit="1.60"/>
                    <measurement group_id="O2" value="11.05" spread="4.67" lower_limit="0.65" upper_limit="1.25"/>
                    <measurement group_id="O3" value="2.97" spread="3.33" lower_limit="1.60" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt;75th Percentile (n=100,90,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="2.28" lower_limit="0.69" upper_limit="1.04"/>
                    <measurement group_id="O2" value="8.25" spread="2.29" lower_limit="0.73" upper_limit="1.11"/>
                    <measurement group_id="O3" value="2.94" spread="1.75" lower_limit="0.46" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 high (n=63,62,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="2.62"/>
                    <measurement group_id="O2" value="11.62" spread="3.23"/>
                    <measurement group_id="O3" value="4.52" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 low (n=57,55,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="3.09"/>
                    <measurement group_id="O2" value="3.87" spread="2.50"/>
                    <measurement group_id="O3" value="0.13" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PBEC &gt;=150 cells/mcgL (n=81,89,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.32"/>
                    <measurement group_id="O2" value="10.97" spread="2.71"/>
                    <measurement group_id="O3" value="4.67" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PBEC &lt;150 cells/mcgL (n=39,34,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="3.89"/>
                    <measurement group_id="O2" value="5.75" spread="3.75"/>
                    <measurement group_id="O3" value="-0.40" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PBEC &gt;=300 cells/mcgL (n=45,51,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="2.88"/>
                    <measurement group_id="O2" value="14.04" spread="3.88"/>
                    <measurement group_id="O3" value="4.65" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline PBEC &lt;300 cells/mcgL (n=75,72,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="2.71"/>
                    <measurement group_id="O2" value="6.33" spread="2.57"/>
                    <measurement group_id="O3" value="2.01" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 reversibility &gt;=12% (n=49,36,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.02" spread="3.85"/>
                    <measurement group_id="O2" value="22.78" spread="5.20"/>
                    <measurement group_id="O3" value="11.80" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 reversibility &lt;12% (n=76,92,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="1.90"/>
                    <measurement group_id="O2" value="3.98" spread="1.97"/>
                    <measurement group_id="O3" value="-1.66" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 asthma exacerbations (n=84,81,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="2.16"/>
                    <measurement group_id="O2" value="8.99" spread="2.41"/>
                    <measurement group_id="O3" value="3.57" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2 but &lt; 6 asthma exacerbations (n=41,49,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="4.12"/>
                    <measurement group_id="O2" value="9.32" spread="4.05"/>
                    <measurement group_id="O3" value="1.63" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic OCS use (n=20,21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="5.82"/>
                    <measurement group_id="O2" value="6.96" spread="6.56"/>
                    <measurement group_id="O3" value="-0.48" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without chronic OCS use (n=105,109,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="2.10"/>
                    <measurement group_id="O2" value="9.52" spread="2.22"/>
                    <measurement group_id="O3" value="3.45" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>6.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>13.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.874</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.54</ci_lower_limit>
            <ci_upper_limit>7.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>7.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>13.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.745</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.48</ci_lower_limit>
            <ci_upper_limit>7.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>7.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>12.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.863</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.93</ci_lower_limit>
            <ci_upper_limit>4.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.221</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>6.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>16.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>8.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.91</ci_lower_limit>
            <ci_upper_limit>19.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>9.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.57</ci_lower_limit>
            <ci_upper_limit>21.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.908</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.19</ci_lower_limit>
            <ci_upper_limit>12.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>6.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>11.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.635</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.84</ci_lower_limit>
            <ci_upper_limit>6.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>8.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>15.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.280</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>3.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.19</ci_lower_limit>
            <ci_upper_limit>11.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>3.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>9.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.691</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.99</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>8.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.85</ci_lower_limit>
            <ci_upper_limit>14.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.177</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>4.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.92</ci_lower_limit>
            <ci_upper_limit>10.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>6.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>14.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.857</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.63</ci_lower_limit>
            <ci_upper_limit>7.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>13.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.28</ci_lower_limit>
            <ci_upper_limit>22.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>5.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>14.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>4.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>10.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 300 cells/μ</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.804</p_value>
            <method>Baseline peripheral blood eosinophil cou</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.01</ci_lower_limit>
            <ci_upper_limit>6.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;= 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>11.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>21.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;= 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.887</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.19</ci_lower_limit>
            <ci_upper_limit>10.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt; 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>7.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.76</ci_lower_limit>
            <ci_upper_limit>12.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt; 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.268</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.15</ci_lower_limit>
            <ci_upper_limit>7.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>7.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.64</ci_lower_limit>
            <ci_upper_limit>13.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>2.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>7.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>6.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>15.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.986</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.50</ci_lower_limit>
            <ci_upper_limit>9.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.912</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.70</ci_lower_limit>
            <ci_upper_limit>16.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.76</ci_lower_limit>
            <ci_upper_limit>14.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>7.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.76</ci_lower_limit>
            <ci_upper_limit>12.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.51</ci_lower_limit>
            <ci_upper_limit>6.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups</title>
        <description>Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups</title>
          <description>Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline SP &gt;= Median (n= 51, 65, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.15" lower_limit="0.88" upper_limit="1.43"/>
                    <measurement group_id="O2" value="-1.18" spread="0.13" lower_limit="0.65" upper_limit="1.08"/>
                    <measurement group_id="O3" value="-0.85" spread="0.14" lower_limit="1.03" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt; Median (n= 67, 50, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.14" lower_limit="0.55" upper_limit="0.95"/>
                    <measurement group_id="O2" value="-0.81" spread="0.15" lower_limit="0.76" upper_limit="1.25"/>
                    <measurement group_id="O3" value="-1.03" spread="0.17" lower_limit="0.45" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &gt;= 25th Percentile (n= 82, 92, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.12" lower_limit="0.75" upper_limit="1.15"/>
                    <measurement group_id="O2" value="-1.04" spread="0.11" lower_limit="0.67" upper_limit="1.03"/>
                    <measurement group_id="O3" value="-0.93" spread="0.13" lower_limit="0.87" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt; 25th Percentile (n= 36, 23, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.19" lower_limit="0.58" upper_limit="1.16"/>
                    <measurement group_id="O2" value="-0.95" spread="0.24" lower_limit="0.81" upper_limit="1.56"/>
                    <measurement group_id="O3" value="-0.92" spread="0.24" lower_limit="0.38" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &gt;= 75th Percentile (n= 25, 34, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.14" lower_limit="0.76" upper_limit="1.60"/>
                    <measurement group_id="O2" value="-1.25" spread="0.18" lower_limit="0.65" upper_limit="1.25"/>
                    <measurement group_id="O3" value="-1.01" spread="0.23" lower_limit="1.60" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt; 75th Percentile (n= 93, 81, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.12" lower_limit="0.69" upper_limit="1.04"/>
                    <measurement group_id="O2" value="-0.92" spread="0.12" lower_limit="0.73" upper_limit="1.11"/>
                    <measurement group_id="O3" value="-0.91" spread="0.13" lower_limit="0.46" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 High (n= 59, 56, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.13"/>
                    <measurement group_id="O2" value="-1.10" spread="0.15"/>
                    <measurement group_id="O3" value="-1.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 Low (n= 55, 47, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.16"/>
                    <measurement group_id="O2" value="-0.94" spread="0.14"/>
                    <measurement group_id="O3" value="-0.87" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &gt;= 150 Cells/UL (n= 77, 78, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.13"/>
                    <measurement group_id="O2" value="-1.07" spread="0.13"/>
                    <measurement group_id="O3" value="-0.94" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &lt; 150 Cells/UL (n= 37, 31, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.18"/>
                    <measurement group_id="O2" value="-0.92" spread="0.16"/>
                    <measurement group_id="O3" value="-1.02" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &gt;= 300 Cells/UL (n= 43, 44, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.15"/>
                    <measurement group_id="O2" value="-1.24" spread="0.16"/>
                    <measurement group_id="O3" value="-0.91" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &lt; 300 Cells/UL (n= 71, 65, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.14"/>
                    <measurement group_id="O2" value="-0.88" spread="0.12"/>
                    <measurement group_id="O3" value="-1.00" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 Reversibility &gt;= 12% (n= 43, 33, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.19"/>
                    <measurement group_id="O2" value="-0.90" spread="0.18"/>
                    <measurement group_id="O3" value="-0.76" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 Reversibility &lt; 12% (n= 73, 78, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.11"/>
                    <measurement group_id="O2" value="-1.12" spread="0.12"/>
                    <measurement group_id="O3" value="-1.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Asthma Exacerbations (n= 79, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.13"/>
                    <measurement group_id="O2" value="-0.94" spread="0.13"/>
                    <measurement group_id="O3" value="-0.95" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 Asthma Exacerbations (n= 39, 43, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.17"/>
                    <measurement group_id="O2" value="-1.15" spread="0.15"/>
                    <measurement group_id="O3" value="-0.90" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Chronic OCS Use (n= 20, 17, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.25"/>
                    <measurement group_id="O2" value="-0.89" spread="0.28"/>
                    <measurement group_id="O3" value="-0.16" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Chronic OCS Use (n= 98, 98, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.11"/>
                    <measurement group_id="O2" value="-1.04" spread="0.11"/>
                    <measurement group_id="O3" value="-1.08" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.759</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.936</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin&gt;= 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.343</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin&gt;= 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.928</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.259</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.775</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.404</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.161</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.540</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 150 cells/μ</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.725</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;= 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;= 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt; 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.652</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt; 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.905</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.513</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.974</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.613</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.165</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups</title>
        <description>AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups</title>
          <description>AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline SP &gt;= Median (n= 46, 63, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.15" lower_limit="0.88" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.10" spread="0.14" lower_limit="0.65" upper_limit="1.08"/>
                    <measurement group_id="O3" value="0.95" spread="0.17" lower_limit="1.03" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt; Median ( n= 61, 46, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.14" lower_limit="0.55" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.95" spread="0.15" lower_limit="0.76" upper_limit="1.25"/>
                    <measurement group_id="O3" value="1.07" spread="0.17" lower_limit="0.45" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &gt;= 25th Percentile (n= 73, 88, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.12" lower_limit="0.75" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.08" spread="0.11" lower_limit="0.67" upper_limit="1.03"/>
                    <measurement group_id="O3" value="0.98" spread="0.14" lower_limit="0.87" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt; 25th Percentile (n= 34, 21, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.19" lower_limit="0.58" upper_limit="1.16"/>
                    <measurement group_id="O2" value="0.84" spread="0.24" lower_limit="0.81" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.09" spread="0.24" lower_limit="0.38" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &gt;= 75th Percentile (n= 23, 33, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.17" lower_limit="0.76" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.20" spread="0.19" lower_limit="0.65" upper_limit="1.25"/>
                    <measurement group_id="O3" value="1.13" spread="0.28" lower_limit="1.60" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SP &lt; 75th Percentile (n= 84, 76, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.12" lower_limit="0.69" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.97" spread="0.12" lower_limit="0.73" upper_limit="1.11"/>
                    <measurement group_id="O3" value="0.96" spread="0.13" lower_limit="0.46" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 high (n=54,52,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.13"/>
                    <measurement group_id="O2" value="1.12" spread="0.15"/>
                    <measurement group_id="O3" value="1.12" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Th2 low (n= 49, 45, 44 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.17"/>
                    <measurement group_id="O2" value="0.88" spread="0.15"/>
                    <measurement group_id="O3" value="0.94" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &gt;= 150 Cells/UL (n=69, 72, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.11"/>
                    <measurement group_id="O2" value="1.06" spread="0.13"/>
                    <measurement group_id="O3" value="1.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC&lt; 150 Cells/UL (n= 34, 31, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.20"/>
                    <measurement group_id="O2" value="0.93" spread="0.13"/>
                    <measurement group_id="O3" value="1.05" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &gt;= 300 Cells/UL (n= 39, 40, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.15"/>
                    <measurement group_id="O2" value="0.98" spread="0.17"/>
                    <measurement group_id="O3" value="0.82" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EC &lt; 300 Cells/UL (N= 64, 63, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.14"/>
                    <measurement group_id="O2" value="1.05" spread="0.13"/>
                    <measurement group_id="O3" value="1.15" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 Reversibility &gt;= 12% (n= 39, 29, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.17"/>
                    <measurement group_id="O2" value="1.14" spread="0.16"/>
                    <measurement group_id="O3" value="0.95" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 Reversibility &lt; 12% (n= 66, 76, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.13"/>
                    <measurement group_id="O2" value="1.04" spread="0.13"/>
                    <measurement group_id="O3" value="1.04" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Asthma Exacerbations (n=73, 68, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.13"/>
                    <measurement group_id="O2" value="1.09" spread="0.14"/>
                    <measurement group_id="O3" value="1.14" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 Asthma Exacerbations (n= 34, 41, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.16"/>
                    <measurement group_id="O2" value="0.96" spread="0.14"/>
                    <measurement group_id="O3" value="0.73" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Chronic OCS Use (n= 17, 16, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.19"/>
                    <measurement group_id="O2" value="0.87" spread="0.29"/>
                    <measurement group_id="O3" value="0.26" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Chronic OCS Use (n= 90, 93, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.11"/>
                    <measurement group_id="O2" value="1.07" spread="0.11"/>
                    <measurement group_id="O3" value="1.14" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.211</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.397</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.315</p_value>
            <method>Repeated Measure Model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; median</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.262</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;= 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.379</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.387</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 25th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;=75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &gt;=75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.775</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline serum periostin &lt; 75th percentile</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.404</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 high</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Th2 low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.540</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Th2 low</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;=150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.295</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;=150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.406</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 150 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &gt;= 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline peripheral blood eosinophil count &lt; 300 cells/μL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;= 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &gt;= 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt; 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.964</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline FEV1 reversibility &lt; 12%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.260</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>&gt; 2 but &lt; 6 asthma exacerbations in the past year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.398</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.327</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Repeated measure model</method>
            <param_type>Difference of LS-mean</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Atopic and Non-atopic asthma status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Atopic and Non-atopic asthma status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atopic asthma (n=96,105,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.67" upper_limit="1.06"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.73" upper_limit="1.11"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.67" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-atopic asthma (n=51,42,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.77" upper_limit="1.39"/>
                    <measurement group_id="O2" value="0.82" lower_limit="0.56" upper_limit="1.15"/>
                    <measurement group_id="O3" value="1.10" lower_limit="0.82" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Atopic asthma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.803</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Atopic asthma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.457</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-atopic asthma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-atopic asthma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.794</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate (AER) by Chronic OCS Use</title>
        <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup chronic OCS use. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Week 1 up to Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate (AER) by Chronic OCS Use</title>
          <description>Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup chronic OCS use. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>AER events/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With chronic OCS use (n=27,26,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="0.93" upper_limit="1.94"/>
                    <measurement group_id="O2" value="2.04" lower_limit="1.51" upper_limit="2.69"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.62" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without chronic OCS use (124,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.66" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.54" upper_limit="0.84"/>
                    <measurement group_id="O3" value="0.74" lower_limit="0.59" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.614</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.506</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Without chronic OCS use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.531</p_value>
            <method>Poisson regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs &gt;2 but =&lt;6), atopic asthma status, chronic OCS use and geographical region as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Nighttime Awakening at Week 53</title>
        <description>Scores for nighttime awakenings were generated based on the single item (question 5) that had a dichotomous response option (YES/NO). Nighttime awakenings were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated with data from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
        <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Nighttime Awakening at Week 53</title>
          <description>Scores for nighttime awakenings were generated based on the single item (question 5) that had a dichotomous response option (YES/NO). Nighttime awakenings were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated with data from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 - Day -1 (Baseline) (n=151,147,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.42"/>
                    <measurement group_id="O2" value="0.42" spread="0.43"/>
                    <measurement group_id="O3" value="0.43" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365 - Day 371 (n=113,108,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.43"/>
                    <measurement group_id="O2" value="-0.18" spread="0.37"/>
                    <measurement group_id="O3" value="-0.23" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Activity Limitations at Week 53</title>
        <description>There were 3 activity limitation questions in the ASMA diary. All activity questions were scored from 0 to 4 and averaged, where the higher score indicated greater limitation. Activity limitation scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Activity Limitations at Week 53</title>
          <description>There were 3 activity limitation questions in the ASMA diary. All activity questions were scored from 0 to 4 and averaged, where the higher score indicated greater limitation. Activity limitation scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -7 - Day -1 (Baseline) (n=151,147,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.86"/>
                    <measurement group_id="O2" value="1.52" spread="0.90"/>
                    <measurement group_id="O3" value="1.63" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365 - Day 371 (n=113,108,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.81"/>
                    <measurement group_id="O2" value="-0.38" spread="0.84"/>
                    <measurement group_id="O3" value="-0.48" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53</title>
        <description>Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for FEV1 was measured in liters.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53</title>
          <description>Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for FEV1 was measured in liters.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change in liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator(BD): Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.926" spread="0.050"/>
                    <measurement group_id="O2" value="1.922" spread="0.056"/>
                    <measurement group_id="O3" value="1.934" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.153" spread="0.053"/>
                    <measurement group_id="O2" value="2.094" spread="0.061"/>
                    <measurement group_id="O3" value="2.110" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-BD:Change from baseline to W53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.99"/>
                    <measurement group_id="O2" value="9.11" spread="2.13"/>
                    <measurement group_id="O3" value="2.94" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD:Change from baseline to W53(n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.39"/>
                    <measurement group_id="O2" value="5.98" spread="1.85"/>
                    <measurement group_id="O3" value="0.18" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53</title>
        <description>Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for FEV6 was measured in liters.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53</title>
          <description>Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for FEV6 was measured in liters.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change in liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator(BD): Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.830" spread="0.064"/>
                    <measurement group_id="O2" value="2.809" spread="0.072"/>
                    <measurement group_id="O3" value="2.827" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.055" spread="0.067"/>
                    <measurement group_id="O2" value="2.981" spread="0.075"/>
                    <measurement group_id="O3" value="2.980" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-BD:Change from baseline to W53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.29"/>
                    <measurement group_id="O2" value="5.75" spread="1.53"/>
                    <measurement group_id="O3" value="1.10" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD:Change from baseline to W53(n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.04"/>
                    <measurement group_id="O2" value="3.27" spread="1.36"/>
                    <measurement group_id="O3" value="-0.11" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53</title>
        <description>Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for FVC was measured in liters.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53</title>
          <description>Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for FVC was measured in liters.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change in liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator(BD): Baseline (n=147,146,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.003" spread="0.069"/>
                    <measurement group_id="O2" value="2.955" spread="0.075"/>
                    <measurement group_id="O3" value="2.993" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD: Baseline (n=147,141,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.225" spread="0.072"/>
                    <measurement group_id="O2" value="3.133" spread="0.078"/>
                    <measurement group_id="O3" value="3.125" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-BD:Change from baseline to W53 (n=125,130,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="1.31"/>
                    <measurement group_id="O2" value="5.43" spread="1.60"/>
                    <measurement group_id="O3" value="0.46" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD:Change from baseline to W53(n=125,126,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="1.01"/>
                    <measurement group_id="O2" value="2.56" spread="1.27"/>
                    <measurement group_id="O3" value="-0.26" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53</title>
        <description>Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for IC was measured in liters.</description>
        <time_frame>Baseline and Week 53</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53</title>
          <description>Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Baseline for IC was measured in liters.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change in liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-bronchodilator(BD): Baseline (n=140,138,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.001"/>
                    <measurement group_id="O2" value="0.023" spread="0.001"/>
                    <measurement group_id="O3" value="0.023" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD: Baseline (n=140,133,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.001"/>
                    <measurement group_id="O2" value="0.024" spread="0.001"/>
                    <measurement group_id="O3" value="0.024" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-BD:Change from baseline to W53 (n=108,109,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" spread="3.42"/>
                    <measurement group_id="O2" value="0.15" spread="2.21"/>
                    <measurement group_id="O3" value="11.38" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BD:Change from baseline to W53(n=108,109,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="3.17"/>
                    <measurement group_id="O2" value="8.33" spread="3.14"/>
                    <measurement group_id="O3" value="3.17" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home</title>
        <description>Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home</title>
          <description>Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 365-371: Morning (n=123,119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.96" spread="3.27"/>
                    <measurement group_id="O2" value="1.67" spread="2.83"/>
                    <measurement group_id="O3" value="1.70" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365-371: Evening (n=119,116,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="3.01"/>
                    <measurement group_id="O2" value="-2.69" spread="3.17"/>
                    <measurement group_id="O3" value="-5.78" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home</title>
        <description>The PEF is a participant’s maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
        <time_frame>Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)</time_frame>
        <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Total</title>
            <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg, Q2W - Cohort 1</title>
            <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tralokinumab 300 mg, Q2/4W - Cohort 2</title>
            <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home</title>
          <description>The PEF is a participant’s maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms.</description>
          <population>The ITT population included all participants who were randomized into the study. Here &quot;n&quot; signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 365-371: Morning (n=123,119,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.89" spread="3.09"/>
                    <measurement group_id="O2" value="-0.64" spread="3.26"/>
                    <measurement group_id="O3" value="-2.80" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 365-371: Evening (n=129,116,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.95" spread="2.99"/>
                    <measurement group_id="O2" value="-6.62" spread="3.13"/>
                    <measurement group_id="O3" value="-11.45" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 75</time_frame>
      <desc>The safety population included all subjects who received any investigational product and had safety data available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Total</title>
          <description>Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
        </group>
        <group group_id="E2">
          <title>Tralokinumab 300 mg Q2W</title>
          <description>Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Tralokinumab 300 mg Q2/4W</title>
          <description>Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diabetic gastropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Testicular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="13" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="58" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E3" events="15" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="90" subjects_affected="15" subjects_at_risk="151"/>
                <counts group_id="E2" events="23" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" events="61" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="32" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="48" subjects_affected="22" subjects_at_risk="151"/>
                <counts group_id="E2" events="44" subjects_affected="27" subjects_at_risk="150"/>
                <counts group_id="E3" events="27" subjects_affected="20" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="83" subjects_affected="40" subjects_at_risk="151"/>
                <counts group_id="E2" events="57" subjects_affected="35" subjects_at_risk="150"/>
                <counts group_id="E3" events="62" subjects_affected="26" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="151"/>
                <counts group_id="E2" events="36" subjects_affected="20" subjects_at_risk="150"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="151"/>
                <counts group_id="E2" events="38" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="14" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="175" subjects_affected="73" subjects_at_risk="151"/>
                <counts group_id="E2" events="192" subjects_affected="68" subjects_at_risk="150"/>
                <counts group_id="E3" events="188" subjects_affected="58" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" events="16" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Meena Jain, MB BChir, Director, Clinical Development,</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>JainM@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

